Moderna shares jumping by 177% after its melanoma vaccine, developed by Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial, just shows the exact risk-benefit schema of investing in pharmaceutical companies. A brilliant breakthrough like the abovementioned could set new historic records and push the stock higher than ever, but also most of the time experiments fail and trials don't pass the tests. Congratulations to Moderna holders, but I for one will definitely not FOMO or regret not having a position in the stock because I know my own investing strategy.